Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Denali Therapeutics (DNLI) Return on Capital Employed (2018 - 2025)

Denali Therapeutics (DNLI) has disclosed Return on Capital Employed for 8 consecutive years, with 0.54% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Capital Employed fell 18.0% to 0.54% in Q3 2025 year-over-year; TTM through Sep 2025 was 0.54%, a 18.0% decrease, with the full-year FY2024 number at 0.42%, down 26.0% from a year prior.
  • Return on Capital Employed was 0.54% for Q3 2025 at Denali Therapeutics, down from 0.47% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.03% in Q2 2021 to a low of 0.54% in Q3 2025.
  • A 5-year average of 0.26% and a median of 0.3% in 2022 define the central range for Return on Capital Employed.
  • Peak YoY movement for Return on Capital Employed: skyrocketed 43bps in 2021, then crashed -37bps in 2022.
  • Denali Therapeutics' Return on Capital Employed stood at 0.28% in 2021, then fell by -23bps to 0.35% in 2022, then skyrocketed by 49bps to 0.18% in 2023, then crashed by -111bps to 0.37% in 2024, then crashed by -44bps to 0.54% in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Return on Capital Employed are 0.54% (Q3 2025), 0.47% (Q2 2025), and 0.42% (Q1 2025).